
AF in Chronic Aortic Regurgitation Tied to Mortality Risk
Atrial fibrillation (AF) was present in 1 in 6 patients with chronic aortic regurgitation — either moderate-to-severe or severe — and was independently associated with an increased risk for mortality and more severe symptoms.
METHODOLOGY:
Researchers conducted a retrospective cohort study to determine the prevalence and prognostic significance of AF in patients with hemodynamically significant aortic regurgitation.
The study included 1006 patients (mean age, 59 years; 82% men) with moderate-to-severe chronic aortic regurgitation between March 2004 and April 2019.
AF was identified using ECG and episodes were recorded by implanted cardiac devices.
The primary endpoint was all-cause mortality. Inclusion was halted for patients who received an aortic valve replacement.
TAKEAWAY:
AF was present in 16% of patients at the time of diagnosis of chronic aortic regurgitation. Those with AF were more likely to be older (adjusted odds ratio [aOR] per year increase, 1.06), men (aOR, 3.55), and have a diagnosis of congestive heart failure (aOR, 2.11; P ≤ .001 for all).
AF was independently associated with a significantly elevated risk for mortality in all three multivariable models even after adjusting for comorbid conditions and left ventricular systolic and diastolic function, with hazard ratios ranging from 1.61 to 2.21 (P < .05 for all).
Patients with AF had more severe symptoms and a higher risk for death than those with sinus rhythm (P < .05 for both).
The median duration between the diagnoses of AF and aortic regurgitation was 2.1 years, and AF was usually paroxysmal.
IN PRACTICE:
The findings 'highlight the need for a more comprehensive evaluation of cardiac function, including assessment of AF, in patients with chronic, hemodynamically significant [aortic regurgitation] rather than focusing solely' on left ventricle systolic function, the researchers reported. The results also underscore the need for prospective studies 'to validate risk factors for the development of AF in chronic [aortic regurgitation] and to assess whether the onset of AF could aid in risk stratification, including the timing of intervention,' they added.
SOURCE:
This study was led by Giordano M. Pugliesi, MD, of the University of Milan-Bicocca in Milan, Italy. It was published online on July 16, 2025, in Heart. The findings were previously presented as a poster at the American College of Cardiology (ACC) Scientific Session 2025 in Chicago.
LIMITATIONS:
The retrospective analysis had incomplete data on comorbidities, cerebral embolic events, hospitalizations for heart failure, and causes of death. Lack of systematic screening may have underestimated the prevalence of AF. This study was conducted at a single tertiary center, potentially introducing referral bias.
DISCLOSURES:
This study received support through an intramural grant by Mayo Clinic. The authors declared having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
July 28 - Atai Life Sciences (NASDAQ:ATAI) shares slid 9% in pre?market trading on Monday after Recognify Life Sciences, an Atai?backed company, reported its Phase 2b trial of inidascamine for cognitive impairment linked to schizophrenia missed its primary endpoint. Warning! GuruFocus has detected 6 Warning Signs with ATAI. The oral compound, engineered to modulate multiple neurotransmitter pathways for pro?cognitive effects, failed to outperform placebo on key cognitive measures. Recognify said the results fell short of statistical significance. Atai's CEO acknowledged the setback but highlighted inidascamine's potential in CIAS and other indications. He added that Atai will redirect its efforts toward its wholly?owned psychedelic programs focused on affective disorders. Investors have been closely watching Atai's broader pipeline, which includes compounds targeting depression, PTSD and Alzheimer's disease. This latest trial disappointment adds to a string of mid?stage readouts that have tested market sentiment around biotech firms pivoting to next?generation neuroscience therapies. Despite today's drop, Atai's management reiterated its commitment to advancing its lead psychedelic candidates through upcoming Phase 1 and Phase 2 trials. Based on the one year price targets offered by 6 analysts, the average target price for ATAI Life Sciences NV is $9.83 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies a upside of +175.44% from the current price of $3.57. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Parents call on FDA for path forward after Duchenne's gene therapy pause
The Food and Drug Administration has paused distribution of the gene therapy Elevidys following the death of a third patient receiving treatment for muscular dystrophy. Alison and William Small are urging the agency to restore access to the drug, the only FDA-approved treatment for Duchenne's muscular dystrophy. Speaking to 'Morning in America,' the Smalls call for transparency and a clear path forward from federal regulators. They say families affected by Duchenne's deserve to understand the risks and that many believe the treatment is worth fighting for. Solve the daily Crossword


Gizmodo
8 minutes ago
- Gizmodo
Your Nature Photos Are Doing More Science Than You Think
With a smartphone in hand, anyone can be a naturalist. Apps like iNaturalist have surged in popularity over the last 15 years, with millions using them to document wildlife around the world. A new study shows that these observations contribute a deluge of data to scientific research. Use of iNaturalist has skyrocketed since its launch in 2008. This citizen science database now contains more than 200 million observations logged by over 3 million users globally, according to research published Monday, July 28, in the journal BioScience. This study is the first to comprehensively quantify how everyday people are contributing to biodiversity science through iNaturalist, coauthor Corey Callaghan, a global change ecologist at the University of Florida, told Gizmodo. He and his colleagues conducted a review of thousands of research articles, finding that the number of peer-reviewed studies using iNaturalist data surged more than tenfold in the last five years. 'Beyond documenting where species occur, the photos uploaded to iNaturalist offer a rich source of biological information—capturing habitat, species coloration, behavior, and more,' lead author Brittany Mason, data management analyst in Callaghan's research group, told Gizmodo in an email. 'Researchers are increasingly using this imagery data as a valuable source of ecological and behavioral data.' The rise of iNaturalist has ushered in a new era of citizen science. This free app—available for both iOS and Android—allows users to record wildlife observations and share their data with research partners such as the Global Biodiversity Information Facility (GBIF). Unlike some other apps that use AI to identify species, iNaturalist relies on its vast community of users for this task. 'Humans need to confirm the identification in order for it to go to research grade,' Callaghan said. This collaborative approach produces a wealth of rigorously vetted data that scientists can use to support their research. 'Many iNaturalist contributors aren't scientists by training, but the platform's user-friendly design empowers anyone to meaningfully participate in scientific discovery,' Mason said. Over 3.5 million iNaturalist users are now helping researchers track species ranges, detect invasive species, monitor climate impacts, and even discover new species, according to Callaghan. In 2011, for example, a user in Columbia documented this century's first confirmed record of the Columbian Weasel—an extremely rare species. No one had ever photographed one alive before, and this iNaturalist user's observation contributed to a 2019 study of its distribution in protected areas. The review shows that iNaturalist data have become pervasive in scientific literature, appearing in papers from 128 countries for over 638 taxonomic families. In the face of a global biodiversity crisis, there is an urgent need for cost-effective and efficient methods to document and assess the status of species, the authors state. As of 2022, 211 plant and animal species had gone extinct in the U.S. alone, and 2,288 were threatened or endangered, according to the Center for Sustainable Systems at the University of Michigan. As individuals, it's easy to feel powerless in a situation like this. This study shows, however, that citizen science is playing an increasingly important role in efforts to monitor, protect, and conserve species. The exponential growth of iNaturalist observations over the past several years has 'fundamentally shifted' the landscape of biodiversity research, Callaghan said, and it doesn't appear to be slowing down anytime soon. 'Thinking about what's coming five, ten years from now—it's mind-boggling,' Callaghan said. 'We still don't know the potential.